Form 4: Quince Therapeutics President Acquires Shares in Open Market
SEC Form 4 Filing
Charles S. Ryan, President of Quince Therapeutics, recently purchased 48,387 shares of QNCX common stock at an average price of $0.65.
Summary
- On August 20, 2024, Charles S. Ryan, President of Quince Therapeutics, acquired 48,387 shares of common stock.
- The shares were purchased at a weighted average price of $0.65, with individual transactions ranging from $0.62 to $0.66.
- Following the transaction, Ryan directly owns 122,461 shares of Quince Therapeutics.
Sentiment
Score: 6
Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's prospects. However, the scale of the purchase is relatively small, so the impact is moderate.
Positives
- The purchase by a company insider could be interpreted as a positive signal about the company's prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's confidence in the company's future performance. However, it's just one data point and should be considered alongside other factors.
Stakeholder Impact
- The insider purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of the transaction where Charles S. Ryan acquired shares of Quince Therapeutics. |
| 08/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.